The ACVR1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used HeLa cell line. This heterogeneous pool carries targeted disruptions in the ACVR1 gene, enabling robust assessment of ACVR1-dependent functions without clonal variability. It serves as a versatile tool for studying BMP receptor signaling and related pathological mechanisms in a cervical adenocarcinoma context.
The parental HeLa line, the first immortal human cell line, was derived from a cervical adenocarcinoma in 1951. These epithelial cells are a cornerstone of cancer research due to their robust growth, well-characterized signaling, and extensive use in functional genomics and drug discovery. They retain key features of transformed cervical epithelium, making them ideal for studying ACVR1-mediated effects on proliferation and differentiation.
ACVR1 encodes the type I BMP receptor, a serine/threonine kinase that initiates intracellular signaling upon binding of BMP ligands such as BMP2, BMP4, BMP7, and BMP9. Ligand engagement promotes formation of heteromeric complexes with type II receptors (BMPR2, ACVR2A, ACVR2B) and accessory co-receptors endoglin and betaglycan, resulting in phosphorylation of receptor-regulated SMAD1, SMAD5, and SMAD8. These phosphorylated SMADs complex with SMAD4, translocate to the nucleus, and directly regulate downstream transcriptional targets including the ID genes ID1, ID2, and ID3. ACVR1 activity is modulated by FKBP12 and hemojuvelin. Through this cascade, ACVR1 governs osteoblast differentiation, chondrogenesis, and tissue homeostasis, while aberrant signaling contributes to heterotopic ossification and tumor progression.
In the HeLa cervical adenocarcinoma model, ACVR1 knockout enables dissection of BMP-mediated effects on proliferation, migration, and survival, thereby separating canonical BMP signaling from other TGF-?? superfamily pathways. While gain-of-function ACVR1 mutations cause FOP and DIPG, wild-type knockout facilitates comparative mutant versus null studies and drug screening for ACVR1 inhibitors in a relevant cancer context.
This polyclonal knockout cell population is well-suited for representative functional assays such as phospho-SMAD1/5/8 western blotting, RT-qPCR of ID genes, RNA-seq, BRE-luciferase reporter assays, immunofluorescence, and migration assays. It also supports drug sensitivity studies for ACVR1 modulators, directly relevant to FOP and DIPG therapeutic development. For further details, contact Ascent Research.
